Unique ID issued by UMIN | UMIN000041621 |
---|---|
Receipt number | R000047508 |
Scientific Title | Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer |
Date of disclosure of the study information | 2020/09/15 |
Last modified on | 2023/06/23 14:40:21 |
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer
Japan |
metastatic colorectal cancer
Gastroenterology | Gastrointestinal surgery |
Malignancy
NO
To investigate the safety and efficacy of trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer.
Safety,Efficacy
Incidence of adverse events
Response to treatment
Disease control rate
Objective response rate
Overall survival
Progression free survival
Time to treatment failure
Observational
20 | years-old | <= |
90 | years-old | > |
Male and Female
1. All patients enrolled in clinical trials of trifluridine/tipiracil hydrochloride (FTD/TPI) plus bevacizumab conducted in Japan for which individual case data were available were included.
Nothing in particular
239
1st name | Kentaro |
Middle name | |
Last name | Yamazaki |
Shizuoka Cancer Center
Division of Gastrointestinal Oncology
411-8777
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777
055-989-5222
k.yamazaki@scchr.jp
1st name | Takeshi |
Middle name | |
Last name | Kawakami |
Shizuoka Cancer Center
Division of Gastrointestinal Oncology
411-8777
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777
055-989-5222
t.kawakami@scchr.jp
The 22nd Century Cutting-Edge Medical Informaion Technology Organization
TAIHO PHARMACEUTICAL CO., LTD.
Profit organization
IRB of Shizuoka Cancer Center
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777
055-989-5222
n/a
NO
2020 | Year | 09 | Month | 15 | Day |
Unpublished
Preinitiation
2020 | Year | 08 | Month | 17 | Day |
2020 | Year | 08 | Month | 21 | Day |
2020 | Year | 10 | Month | 01 | Day |
2024 | Year | 07 | Month | 31 | Day |
Incidence of adverse events
Response to treatment
Disease control rate
Objective response rate
Overall survival
Progression free survival
Time to treatment failure
2020 | Year | 08 | Month | 31 | Day |
2023 | Year | 06 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047508
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |